{"id":34233,"date":"2026-03-18T07:12:13","date_gmt":"2026-03-18T07:12:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/34233\/"},"modified":"2026-03-18T07:12:13","modified_gmt":"2026-03-18T07:12:13","slug":"mankind-pharma-acquires-roches-rivotril-brand-for-india-bolsters-cns-presence","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/34233\/","title":{"rendered":"Mankind Pharma acquires Roche\u2019s Rivotril brand for India, bolsters CNS presence"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/1773817933_534_1x1_spacer.png\" alt=\"FILE PHOTO: Mankind Pharma logo is seen in this illustration taken, May 9, 2023.\" title=\"FILE PHOTO: Mankind Pharma logo is seen in this illustration taken, May 9, 2023.\" data-original=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/1773817933_534_1x1_spacer.png\" class=\"article-pictue\"\/><\/p>\n<p class=\"caption\">\n\t\t\t\t\t\t\t\t\t\tFILE PHOTO: Mankind Pharma logo is seen in this illustration taken, May 9, 2023.<br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t| Photo Credit:<br \/>\n\t\t\t\t\t\t\t\t\t\t\tDado Ruvic\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n<p><a href=\"https:\/\/www.thehindubusinessline.com\/stocks\/mankind-pharma-ltd\/\" target=\"_self\" rel=\"nofollow noopener\">Mankind Pharma<\/a> has acquired Rivotril from Roche for the Indian market, with exclusive rights for domestic manufacture, marketing and distribution of the product, the company said. The acquisition bolsters Mankind\u2019s neurological products portfolio.<\/p>\n<p>Rivotril is the innovator reference brand of clonazepam prescribed for the management of neurological and psychiatric conditions, Mankind said.<\/p>\n<p>The acquisition aligns with Mankind Pharma\u2019s focus on chronic therapies, where it has expanded presence through new launches, in-licensing partnerships and portfolio additions.<\/p>\n<p>Atish Majumdar, Senior President, Sales and Marketing, Mankind Pharma Specialty Business, said in a statement, the acquisition was aligned with the company\u2019s \u00a0strategic focus to strengthen its presence in chronic and specialty therapies. \u201cGoing forward, we see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS (central nervous system) therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India,\u201d he said. The company engages with over five lakh doctors.<\/p>\n<p class=\"publish-time\" id=\"end-of-article\">Published on  March 18, 2026 <\/p>\n","protected":false},"excerpt":{"rendered":"FILE PHOTO: Mankind Pharma logo is seen in this illustration taken, May 9, 2023. | Photo Credit: Dado&hellip;\n","protected":false},"author":2,"featured_media":34234,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[20302,20312,20311,20313,134],"class_list":{"0":"post-34233","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-mankind-pharma","9":"tag-mankind-pharma-acquires-rivotril-brand-for-the-indian-market","10":"tag-mankind-pharma-acquires-rivotril-from-roche","11":"tag-rivotril","12":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116248939272745632","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=34233"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34233\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/34234"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=34233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=34233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=34233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}